Osteosarcoma in Dogs: Bone Cancer and Treatment Options

Osteosarcoma is the most common bone cancer in dogs. It's aggressive, painful, and most often affects large and giant breeds. If your dog has been diagnosed with osteosarcoma, you're facing difficult decisions — and you need honest information about what treatment can and cannot do.

This is what you need to know.

What is osteosarcoma?

Osteosarcoma is a malignant tumour of the bone. It most commonly appears in the long bones of the legs — the front legs more than the back, and the areas near joints (the distal radius near the wrist, the proximal humerus near the shoulder, or around the knee). It grows quickly, destroys bone tissue, and causes severe pain.

The tumour itself is often visible on X-rays as an area where bone has been eaten away and replaced with abnormal growth. By the time most dogs show symptoms — limping, swelling, reluctance to put weight on a leg — the tumour has already been growing for weeks.

The bigger problem is metastasis. Osteosarcoma spreads to the lungs early and aggressively. By the time of diagnosis, microscopic lung metastases are often already present, even if they don't yet show up on imaging.

Which dogs are at risk?

Osteosarcoma occurs disproportionately in large and giant breeds. Rottweilers, Irish Wolfhounds, Scottish Deerhounds, and Great Danes all have significantly elevated incidence. The biomechanical stress hypothesis — more weight on long bones — has some epidemiological support, but the genetic component is clear.

Dogs over 40 kg are at much higher risk than smaller dogs. The disease typically affects middle-aged to older dogs (median age 7–9 years), though it can occur in younger animals.

Osteosarcoma can also occur in the jaw, ribs, or pelvis, but appendicular osteosarcoma (limb bones) is the most common form and the most studied.

Symptoms

The first sign is usually limping. The dog may favour one leg, refuse to put weight on it, or show pain when the area is touched. Swelling over the affected bone may be visible or palpable. The limping often worsens over days to weeks.

Because osteosarcoma is painful, some dogs become less active, reluctant to climb stairs, or hesitant to play. In severe cases, the weakened bone can fracture spontaneously — a pathological fracture that occurs with minimal trauma because the tumour has destroyed the bone's structural integrity.

If your dog is limping persistently without an obvious injury, see your vet. X-rays of the affected limb can usually identify osteosarcoma. Definitive diagnosis requires a biopsy.

Current treatment options

The standard of care for appendicular osteosarcoma is amputation of the affected limb followed by chemotherapy with carboplatin.

Surgery

Amputation removes the primary tumour and eliminates the source of pain. Most dogs — even large dogs — adapt well to life on three legs. Recovery takes a few weeks. Quality of life after amputation is generally good.

Limb-sparing surgery (removing the tumour but saving the leg) is possible in select cases, typically for tumours of the distal radius. It requires specialised expertise and is not widely available. Complication rates are higher than with amputation, and not all dogs are candidates.

Without any treatment, median survival is one to two months. With amputation alone (no chemotherapy), median survival is approximately four months. Most dogs die from metastatic disease in the lungs.

Chemotherapy

Carboplatin chemotherapy is given intravenously every three to four weeks for four to six treatments, starting shortly after surgery. It targets microscopic metastases that are already present but not yet detectable on scans.

Carboplatin extends median survival from about four months (surgery alone) to 10–12 months. Approximately 10% of dogs survive two years or longer.

Dogs tolerate carboplatin relatively well. Serious side effects — severe vomiting, diarrhoea, or drops in white blood cell counts requiring hospitalisation — affect fewer than 10% of dogs in most protocols. Most dogs maintain good quality of life during treatment.

Chemotherapy does not cure osteosarcoma. It buys time. Most dogs eventually develop visible lung metastases and decline despite treatment.

Radiation therapy

Radiation is used palliatively when amputation is not an option — either because the owner declines surgery or because the dog has other health conditions that make anaesthesia too risky. Palliative radiation can reduce pain and slow local tumour growth, but it does not address metastatic disease.

Stereotactic radiation (a more precise form requiring specialised equipment) is available at some veterinary centres. It offers better local control than conventional radiation but is expensive and not widely accessible in Europe.

Prognosis — the honest picture

Osteosarcoma is aggressive. Even with amputation and chemotherapy, median survival is 10–12 months. Metastasis to the lungs is the typical cause of death.

Some dogs do better than the median. Approximately 20% survive beyond one year, and a small percentage survive two years or longer. Favourable prognostic factors include younger age at diagnosis, tumours of the distal radius (wrist), and low alkaline phosphatase levels at diagnosis.

But the reality is that most dogs with osteosarcoma will not be cured. Treatment is about quality time — months where the dog is comfortable, active, and free of pain — not years.

This is hard to hear. It's also the truth, and you deserve to know it when deciding how to move forward.

What research is exploring

Personalised mRNA cancer vaccines — the approach showing strong results in human melanoma and pancreatic cancer trials — are being developed for dogs. These vaccines are designed from the individual dog's tumour mutations and train the immune system to recognise and attack cancer cells carrying those mutations.

The science is proven in human trials. In resected melanoma, a personalised vaccine combined with immunotherapy reduced recurrence risk by 49% at five years. In pancreatic cancer — one of the deadliest human cancers — half of vaccinated patients mounted strong immune responses, and those who responded had dramatically better outcomes.

Here's the challenge for osteosarcoma: the approach works best when the tumour carries many mutations, giving the immune system more targets to recognise. A large study of 59 dogs with osteosarcoma found that tumour mutational burden is low. One case had only 21 coding mutations across the entire exome. Fewer mutations mean fewer targets for a vaccine.

Osteosarcoma does carry specific driver mutations. TP53 was found in 71% of cases, SETD2 in 42%, and DMD in 50%. Whether these mutations produce vaccine-targetable neoantigens is an open question that ongoing research is addressing.

Personalised vaccines work best in the adjuvant setting — after surgery, when the immune system only needs to mop up microscopic residual disease. That matches the osteosarcoma treatment timeline. But the low mutational burden means osteosarcoma may be a harder cancer for this approach than melanoma or mast cell tumours.

Novectis Labs is developing personalised mRNA cancer vaccines for dogs based on this human-proven science. The Founding Patient Programme (Pionierprogramm) is accepting applications for a limited number of dogs. Data from every case helps refine the approach and advance the science for future patients.

This is not a guaranteed solution. It is a scientifically rigorous attempt to bring the same tools succeeding in human cancer trials to veterinary oncology — and to learn what works in which cancers.

What you can do

If your dog has been diagnosed with osteosarcoma, talk to a veterinary oncologist. Discuss amputation, chemotherapy, and whether your dog is a candidate for clinical trials or emerging treatments.

Ask about prognosis. Ask about quality of life. Ask what to expect at each stage. You need the truth to make the right decision for your dog.

If you're the owner of a large-breed dog and you're reading this before a diagnosis, the best thing you can do is stay vigilant. Persistent limping without an obvious cause warrants X-rays. Early diagnosis doesn't change the prognosis dramatically, but it gives you more time to plan and more options for treatment.

Osteosarcoma is not a cancer we can cure yet. But we can give dogs good months — pain-free, active, surrounded by the people they love. That matters.